Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Persistence of SARS-CoV-2 RNA shedding and infectivity in immunized population: Prospective study along different epidemiological periods in Argentina.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      During the pandemic of COVID-19, numerous waves of infections affected the two hemispheres with different impacts on each country. Throughout these waves, and with the emergence of new variants, health systems and scientists have tried to provide real-time responses to the complex biology of SARS-CoV-2, dealing with different clinical presentations, biological characteristics, and clinical impact of these variants. In this context, knowing the extent period in which an infected individual releases infectious viral particles has important implications for public health. This work aimed to investigate viral RNA shedding and infectivity of SARS-CoV-2 beyond 10 days after symptom onset (SO). A prospective multicenter study was performed between July/2021 and February/2022 on 116 immunized strategic personnel with COVID-19 diagnosed by RT-qPCR, with asymptomatic (7%), mild (91%) or moderate disease (2%). At the time of diagnosis, 70% had 2 doses of vaccines, 26% had 2 plus a booster, and 4% had one dose. After day 10 from SO, sequential nasopharyngeal swabs were taken to perform RT-qPCR, viral isolation, and S gene sequencing when possible. Viral sequences were obtained in 98 samples: 43% were Delta, 16% Lambda, 15% Gamma, 25% Omicron (BA.1) and 1% Non-VOC/VOI, in accordance with the main circulating variants at each moment. SARS-CoV-2 RNA was detected 10 days post SO in 57% of the subjects. Omicron was significantly less persistent. Noteworthy, infective viruses could not be isolated in any of the samples. In conclusion, a 10-days isolation period was useful to prevent further infections, and proved valid for the variants studied. Recently, even shorter periods have been applied, as the Omicron variant is prevalent, and worldwide population is largely vaccinated. In the future, facing the possible emergence of new variants and considering immunological status, a return to 10 days may be necessary.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2023 Theaux et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Mol Biol Evol. 2022 Feb 3;39(2):. (PMID: 35038741)
      Nat Commun. 2021 Jan 11;12(1):267. (PMID: 33431879)
      N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
      Clin Infect Dis. 2020 Dec 17;71(10):2663-2666. (PMID: 32442256)
      PLoS Pathog. 2018 Jun 28;14(6):e1007015. (PMID: 29953542)
      Nat Rev Microbiol. 2023 Mar;21(3):147-161. (PMID: 36460930)
      Nat Med. 2022 Jul;28(7):1491-1500. (PMID: 35395151)
      Viruses. 2022 Apr 28;14(5):. (PMID: 35632661)
      Viruses. 2023 Jan 22;15(2):. (PMID: 36851525)
      Emerg Infect Dis. 2022 May;28(5):998-1001. (PMID: 35290176)
      J Pathol. 2023 Mar;259(3):254-263. (PMID: 36651103)
      Microbiol Spectr. 2022 Jun 29;10(3):e0050322. (PMID: 35604133)
      Emerg Infect Dis. 2020 Nov;26(11):2701-2704. (PMID: 32749957)
      Emerg Infect Dis. 2020 Oct;26(10):2401-2405. (PMID: 32610037)
      J Infect Dis. 2021 Oct 28;224(8):1362-1371. (PMID: 33649773)
      Cell. 2023 Jan 5;186(1):112-130.e20. (PMID: 36580912)
      Infect Control Hosp Epidemiol. 2023 Apr;44(4):659-662. (PMID: 34866565)
      Euro Surveill. 2020 Aug;25(32):. (PMID: 32794447)
      J Infect Dis. 2021 Oct 28;224(8):1325-1332. (PMID: 34329473)
      Infect Dis (Lond). 2021 Jan;53(1):31-37. (PMID: 32935628)
      Sci Rep. 2022 Nov 4;12(1):18721. (PMID: 36333340)
      J Med Virol. 2022 Nov;94(11):5543-5546. (PMID: 35790476)
      Viruses. 2021 Sep 24;13(10):. (PMID: 34696353)
      Clin Microbiol Infect. 2022 Sep;28(9):1302-1303. (PMID: 35568306)
      Nature. 2020 May;581(7809):465-469. (PMID: 32235945)
      JCI Insight. 2022 Jan 25;7(2):. (PMID: 34871181)
      Front Med (Lausanne). 2021 Dec 10;8:755463. (PMID: 34957143)
      Emerg Infect Dis. 2022 Apr;28(4):901-903. (PMID: 35318924)
      Clin Infect Dis. 2021 Nov 2;73(9):e2952-e2959. (PMID: 33098412)
      J Infect. 2022 Apr;84(4):e7-e9. (PMID: 35143815)
      PLoS Biol. 2022 Jun 1;20(6):e3001687. (PMID: 35648781)
      J Med Virol. 2020 Nov;92(11):2286-2287. (PMID: 32347980)
      BMJ. 2022 Jan 21;376:o184. (PMID: 35063939)
      Nat Commun. 2020 Nov 27;11(1):6059. (PMID: 33247099)
      EBioMedicine. 2022 May;79:104008. (PMID: 35460989)
      J Infect. 2020 Sep;81(3):357-371. (PMID: 32615199)
      Elife. 2022 Nov 16;11:. (PMID: 36383192)
      Nature. 2022 Mar;603(7902):715-720. (PMID: 35104836)
    • الرقم المعرف:
      0 (RNA, Viral)
    • الموضوع:
      SARS-CoV-2 variants
    • الموضوع:
      Date Created: 20230517 Date Completed: 20230519 Latest Revision: 20230615
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC10191317
    • الرقم المعرف:
      10.1371/journal.pone.0285704
    • الرقم المعرف:
      37196044